C4 Therapeutics, Inc. (CCCC) is a publicly traded Healthcare sector company. As of August 10, 2026, CCCC trades at $3.63 with a market cap of $412.42M and a P/E ratio of -3.31. CCCC moved -3.08% today. Year to date, CCCC is +89.53%; over the trailing twelve months it is +44.80%. Its 52-week range spans $1.09 to $5.17. Analyst consensus is strong buy with an average price target of $8.50. Rallies surfaces CCCC's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks politician and congressional stock disclosures for CCCC, including purchases, sales, transaction dates, owners, and reported trade amounts when available.
| Metric | Value |
|---|---|
| Price | $3.63 |
| Market Cap | $412.42M |
| P/E Ratio | -3.31 |
| EPS | $-1.10 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.17 |
| 52-Week Low | $1.09 |
| Volume | 1.63M |
| Avg Volume | 0 |
| Revenue (TTM) | $34.86M |
| Net Income | $-103.80M |
| Gross Margin | 0.00% |
3 analysts cover CCCC: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.50.